SI-Bone (NASDAQ:SIBN) versus Invivo Therapeutics (NASDAQ:NVIV) Head-To-Head Contrast – Tech Know Bits

SI-Bone (NASDAQ:SIBN) and Invivo Therapeutics (NASDAQ:NVIV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Insider & Institutional Ownership

51.0% of SI-Bone shares are held by institutional investors. Comparatively, 4.1% of Invivo Therapeutics shares are held by institutional investors. 38.8% of SI-Bone shares are held by company insiders. Comparatively, 1.5% of Invivo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

This is a breakdown of recent ratings and target prices for SI-Bone and Invivo Therapeutics, as provided by MarketBeat.

SI-Bone currently has a consensus target price of $27.00, indicating a potential upside of 19.84%. Given SI-Bones higher probable upside, analysts clearly believe SI-Bone is more favorable than Invivo Therapeutics.

Profitability

This table compares SI-Bone and Invivo Therapeutics net margins, return on equity and return on assets.

Earnings & Valuation

This table compares SI-Bone and Invivo Therapeutics gross revenue, earnings per share and valuation.

SI-Bone has higher revenue and earnings than Invivo Therapeutics. SI-Bone is trading at a lower price-to-earnings ratio than Invivo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

SI-Bone has a beta of -0.47, suggesting that its share price is 147% less volatile than the S&P 500. Comparatively, Invivo Therapeutics has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.

Summary

SI-Bone beats Invivo Therapeutics on 9 of the 12 factors compared between the two stocks.

About SI-Bone

SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.

About Invivo Therapeutics

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. has research collaboration with the Q Therapeutics, Inc. for the evaluation of the combination of PLGA-PLL based Neuro-Spinal Scaffold with adult neural progenitor cells, including those from induced pluripotent stem cells. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.

Excerpt from:
SI-Bone (NASDAQ:SIBN) versus Invivo Therapeutics (NASDAQ:NVIV) Head-To-Head Contrast - Tech Know Bits